CERVOMED INC (CRVO) Stock Price, Quote, News and Overview
NASDAQ:CRVO - Nasdaq - US15713L1098 - Common Stock - Currency: USD
CRVO Quote, Performance and Key Statistics
8.51
-0.27 (-3.08%)
The current stock price of CRVO is 8.51 USD. In the past month the price decreased by -5.65%. In the past year, price decreased by -54.47%.
CRVO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.7 | 321.60B | ||
| AMGN | AMGEN INC | 13.07 | 145.89B | ||
| GILD | GILEAD SCIENCES INC | 13.92 | 134.11B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.91B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.65 | 65.28B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 38.06B | ||
| ARGX | ARGENX SE - ADR | 99.65 | 35.72B | ||
| ONC | BEIGENE LTD-ADR | 5.89 | 25.49B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
| NTRA | NATERA INC | N/A | 20.54B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.87B | ||
| BIIB | BIOGEN INC | 8.02 | 18.58B |
Related stock screener links
About CRVO
Company Profile
CervoMed, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 15 full-time employees. The company went IPO on 2016-11-09. The company is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. The company is being evaluated in its ongoing RewinD-LB Trial, a Phase 2b study in patients with DLB.
Company Info
CERVOMED INC
20 Park Plaza, Suite 424
Boston MASSACHUSETTS US
Employees: 15
Phone: 16177444400
CERVOMED INC / CRVO FAQ
What is the stock price of CERVOMED INC today?
The current stock price of CRVO is 8.51 USD. The price decreased by -3.08% in the last trading session.
What is the ticker symbol for CERVOMED INC stock?
The exchange symbol of CERVOMED INC is CRVO and it is listed on the Nasdaq exchange.
On which exchange is CRVO stock listed?
CRVO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CERVOMED INC stock?
13 analysts have analysed CRVO and the average price target is 16.15 USD. This implies a price increase of 89.78% is expected in the next year compared to the current price of 8.51. Check the CERVOMED INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CERVOMED INC worth?
CERVOMED INC (CRVO) has a market capitalization of 74.04M USD. This makes CRVO a Micro Cap stock.
How many employees does CERVOMED INC have?
CERVOMED INC (CRVO) currently has 15 employees.
What are the support and resistance levels for CERVOMED INC (CRVO) stock?
CERVOMED INC (CRVO) has a support level at 8.48 and a resistance level at 8.7. Check the full technical report for a detailed analysis of CRVO support and resistance levels.
Is CERVOMED INC (CRVO) expected to grow?
The Revenue of CERVOMED INC (CRVO) is expected to decline by -41.74% in the next year. Check the estimates tab for more information on the CRVO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CERVOMED INC (CRVO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CRVO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CRVO, evaluating the profitability, health, valuation and growth aspects
- CERVOMED INC (CRVO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CERVOMED INC (CRVO) Sales and EPS estimates to see what analysts future expectations are.
- CERVOMED INC (CRVO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CERVOMED INC (CRVO) Insider and Institutional Ownership to learn about the owners and their transactions.
- CERVOMED INC (CRVO) Stock Chart to make your own analysis
- CERVOMED INC (CRVO) Latest news and press-releases to stay up to date.
Does CERVOMED INC (CRVO) stock pay dividends?
CRVO does not pay a dividend.
When does CERVOMED INC (CRVO) report earnings?
CERVOMED INC (CRVO) will report earnings on 2025-08-07.
What is the Price/Earnings (PE) ratio of CERVOMED INC (CRVO)?
CERVOMED INC (CRVO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.18).
What is the Short Interest ratio of CERVOMED INC (CRVO) stock?
The outstanding short interest for CERVOMED INC (CRVO) is 15.58% of its float. Check the ownership tab for more information on the CRVO short interest.
CRVO Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CRVO. When comparing the yearly performance of all stocks, CRVO is one of the better performing stocks in the market, outperforming 98.43% of all stocks.
CRVO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CRVO. While CRVO has a great health rating, there are worries on its profitability.
CRVO Financial Highlights
Over the last trailing twelve months CRVO reported a non-GAAP Earnings per Share(EPS) of -2.18. The EPS decreased by -147.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.81% | ||
| ROE | -41.56% | ||
| Debt/Equity | 0 |
CRVO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to CRVO. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -2.3% and a revenue growth -41.74% for CRVO